Dual monoamine oxidase B and acetylcholine esterase inhibitors for treating movement and cognition deficits in a
6-hydroxydopamine
multi-target
phenotypic screen
polypharmacy
Journal
Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents
ISSN: 1054-2523
Titre abrégé: Med Chem Res
Pays: United States
ID NLM: 9211347
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
entrez:
8
11
2021
pubmed:
9
11
2021
medline:
9
11
2021
Statut:
ppublish
Résumé
Parkinson's disease (PD) is an age-associated neurodegenerative movement disorder that leads to loss of dopaminergic neurons and motor deficits. Approaches to neuroprotection and symptom management in PD include use of monoamine oxidase B (MAO-B) inhibitors. Many patients with PD also exhibit memory loss in the later stages of disease progression, which is treated with acetylcholine esterase (AChE) inhibitors. We sought to identify a dual-mechanism compound that would inhibit both MAO-B and AChE enzymes. Our screen identified a promising compound (7) with balanced MAO-B (IC
Identifiants
pubmed: 34744409
doi: 10.1007/s00044-021-02720-x
pmc: PMC8570587
mid: NIHMS1720470
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1166-1174Subventions
Organisme : NIGMS NIH HHS
ID : P20 GM109098
Pays : United States
Organisme : NINDS NIH HHS
ID : R41 NS110070
Pays : United States
Organisme : NIA NIH HHS
ID : T32 AG052375
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM104942
Pays : United States
Déclaration de conflit d'intérêts
Conflict of Interest: The authors declare that they have no conflict of interest.
Références
Discov Med. 2013 Jan;15(80):61-6
pubmed: 23375015
Chembiochem. 2014 Jul 8;15(11):1591-1598
pubmed: 25045125
Arch Biochem Biophys. 2007 Aug 15;464(2):269-76
pubmed: 17573034
Prog Neurobiol. 2010 Nov;92(3):330-44
pubmed: 20600573
J Neural Transm Suppl. 2000;(60):157-69
pubmed: 11205137
Neurobiology (Bp). 2000;8(1):47-54
pubmed: 11008877
Curr Drug Targets. 2012 Apr;13(4):483-94
pubmed: 22280345
Curr Med Chem. 2013;20(13):1662-72
pubmed: 23410161
Curr Opin Genet Dev. 2017 Jun;44:102-109
pubmed: 28242493
J Vis Exp. 2011 Mar 11;(49):
pubmed: 21445035
Parkinsons Dis. 2012;2012:131058
pubmed: 22966477
Prog Brain Res. 2010;183:59-77
pubmed: 20696315
Neurobiol Aging. 1997 Sep-Oct;18(5):497-507
pubmed: 9390776
Clin Exp Pharmacol Physiol. 2006 Nov;33(11):1052-8
pubmed: 17042914
Neurotherapeutics. 2020 Oct;17(4):1495-1510
pubmed: 33205381
Eur J Pharmacol. 1991 Dec 12;208(4):273-86
pubmed: 1815982
Eur J Med Chem. 2017 Jan 5;125:853-864
pubmed: 27744252
Ageing Res Rev. 2021 Mar;66:101256
pubmed: 33434685
Sci Rep. 2017 Mar 03;7:42717
pubmed: 28256516
Sci Rep. 2019 Oct 31;9(1):15743
pubmed: 31673107
Mov Disord. 2013 Jan;28(1):14-23
pubmed: 23389780
Br J Pharmacol. 2006 Jan;147 Suppl 1:S287-96
pubmed: 16402116
ACS Med Chem Lett. 2011 Oct 15;3(1):39-42
pubmed: 22282722
Parkinsonism Relat Disord. 2020 Dec;81:140-143
pubmed: 33130476
Expert Rev Neurother. 2012 Dec;12(12):1451-66
pubmed: 23237352
Drug Discov Today. 2003 Apr 1;8(7):316-23
pubmed: 12654544
Bioorg Med Chem Lett. 2012 Dec 1;22(23):7183-8
pubmed: 23102654
J Neurol Sci. 1973 Dec;20(4):415-55
pubmed: 4272516
Pharmaceuticals (Basel). 2020 Aug 21;13(9):
pubmed: 32825638
J Med Chem. 2011 Feb 10;54(3):909-12
pubmed: 21175212
J Med Chem. 2020 Jul 9;63(13):6847-6862
pubmed: 32469516
Toxicology. 2013 May 10;307:17-23
pubmed: 23295711
Int Rev Neurobiol. 2011;100:107-25
pubmed: 21971005
Bioorg Med Chem. 2012 Jan 15;20(2):809-18
pubmed: 22197671
Drugs R D. 2007;8(6):349-62
pubmed: 17963426
Prog Neurobiol. 2011 Sep 1;94(4):347-59
pubmed: 21536094
Chem Rev. 2019 Jan 23;119(2):1221-1322
pubmed: 30095897